# Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer

> **NCT00004890** · PHASE1 · COMPLETED · sponsor: **BioMedicines**

## Conditions studied

- Drug Extravasation
- Kidney Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **DRUG:** Biomed 101

## Key facts

- **NCT ID:** NCT00004890
- **Lead sponsor:** BioMedicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** — (—)
- **Last updated:** 2013-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004890, "Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00004890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*